Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Myasthenia gravis
  • Focus Registrational; Therapeutic Use
  • Acronyms REGAIN
  • Sponsors Alexion AstraZeneca Rare Disease; Alexion Pharmaceuticals

    • Most Recent Events

    • 13 Jun 2023 According to an Alexion AstraZeneca Rare Disease, based on comprehensive results from this study Soliris (eculizumab) has been approved in China for the treatment of adult patients with refractory generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.
    • 18 May 2022 Results assessing comparative clinical efficacy and cost-effectiveness in patients with myasthenia gravis using data from three clinical studies: ADAPT, REGAIN and GTI1408 presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 04 Mar 2021 According to an Alexion Pharmaceuticals media release, data from this trial will be presented at 73rd annual meeting of the American Academy of Neurology (AAN)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top